CU Logo University of Colorado Anschutz Medical Campus
Back to Results

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

Primary Objective

This is a first -in-human study. This study mainly aims to test the safety and side effects of the study drugs and to find the best does of AGEN1181 alone and in combination with balstilimab for future studies.

Is This Study For You?

Let's Get Started!

Description

This is a first -in-human study. This study mainly aims to test the safety and side effects of the study drugs and to find the best does of AGEN1181 alone and in combination with balstilimab for future studies.

Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit clinicaltrials.gov to learn more about this study.
Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Breelyn Wilky

Breelyn Wilky

Study ID

Protocol Number: 20-2042

More information available at ClinicalTrials.gov: NCT03860272

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers